Browsing by author "Larkin, James"
Now showing items 21-40 of 75
-
Efficacy and correlative analyses of avelumab plus axitinib versus sunitinib in sarcomatoid renal cell carcinoma: post hoc analysis of a randomized clinical trial.
Choueiri, TK; Larkin, J; Pal, S; Motzer, RJ; Rini, BI; et al. (ELSEVIER, 2021-04-23)BACKGROUND: Among patients with advanced renal cell carcinoma (RCC), those with sarcomatoid histology (sRCC) have the poorest prognosis. This analysis assessed the efficacy of avelumab plus axitinib versus sunitinib in ... -
Efficacy and Safety of Nivolumab Alone or in Combination With Ipilimumab in Patients With Mucosal Melanoma: A Pooled Analysis.
D'Angelo, SP; Larkin, J; Sosman, JA; Lebbé, C; Brady, B; et al. (2017-01)Purpose Mucosal melanoma is an aggressive malignancy with a poor response to conventional therapies. The efficacy and safety of nivolumab (a programmed death-1 checkpoint inhibitor), alone or combined with ipilimumab (a ... -
Efficacy and toxicity of treatment with the anti-CTLA-4 antibody ipilimumab in patients with metastatic melanoma after prior anti-PD-1 therapy.
Bowyer, S; Prithviraj, P; Lorigan, P; Larkin, J; McArthur, G; et al. (2016-05)Background Recent phase III clinical trials have established the superiority of the anti-PD-1 antibodies pembrolizumab and nivolumab over the anti-CTLA-4 antibody ipilimumab in the first-line treatment of patients with ... -
Escape from nonsense-mediated decay associates with anti-tumor immunogenicity.
Litchfield, K; Reading, JL; Lim, EL; Xu, H; Liu, P; et al. (NATURE PUBLISHING GROUP, 2020-07-30)Frameshift insertion/deletions (fs-indels) are an infrequent but highly immunogenic mutation subtype. Although fs-indels are degraded through the nonsense-mediated decay (NMD) pathway, we hypothesise that some fs-indels ... -
EULAR points to consider for the diagnosis and management of rheumatic immune-related adverse events due to cancer immunotherapy with checkpoint inhibitors.
Kostine, M; Finckh, A; Bingham, CO; Visser, K; Leipe, J; et al. (BMJ PUBLISHING GROUP, 2021-01-01)BACKGROUND: Rheumatic and musculoskeletal immune-related adverse events (irAEs) are observed in about 10% of patients with cancer receiving checkpoint inhibitors (CPIs). Given the recent emergence of these events and the ... -
Extensive mucocutaneous, oesophageal and otic lichen planus secondary to nivolumab therapy.
Ferguson, L; Ho, B; Weir, J; Francis, N; West, K; et al. (Wiley, 2021-03-01)We report a 73-year-old female with metastatic renal cell carcinoma who developed a widespread lichenoid reaction following nivolumab treatment. The timeline of the reaction strongly correlated with the nivolumab treatment ... -
External Validation of the 2003 Leibovich Prognostic Score in Patients Randomly Assigned to SORCE, an International Phase III Trial of Adjuvant Sorafenib in Renal Cell Cancer.
Oza, B; Eisen, T; Frangou, E; Stewart, GD; Bex, A; et al. (LIPPINCOTT WILLIAMS & WILKINS, 2022-06-01)PURPOSE: The 2003 Leibovich score guides prognostication and selection to adjuvant clinical trials for patients with locally advanced renal cell carcinoma (RCC) after nephrectomy. We provide a robust external validation ... -
First-line treatment of metastatic clear cell renal cell carcinoma: a decision-making analysis among experts.
Aeppli, S; Schmaus, M; Eisen, T; Escudier, B; Grünwald, V; et al. (ELSEVIER, 2021-01-15)BACKGROUND: The treatment landscape of metastatic clear cell renal cell carcinoma (mccRCC) has been transformed by targeted therapies with tyrosine kinase inhibitors (TKI) and more recently by the incorporation of immune ... -
Health-related quality of life impact of cobimetinib in combination with vemurafenib in patients with advanced or metastatic BRAFV600 mutation-positive melanoma.
Dréno, B; Ascierto, PA; Atkinson, V; Liszkay, G; Maio, M; et al. (NATURE PUBLISHING GROUP, 2018-03-20)BACKGROUND: In the coBRIM study, cobimetinib plus vemurafenib (C+V) significantly improved survival outcomes vs placebo and vemurafenib (P+V) in patients with advanced/metastatic BRAFV600-mutated melanoma. An analysis of ... -
How clinical practice is changing the rules: the sunitinib 2/1 schedule in metastatic renal cell carcinoma.
Bracarda, S; Negrier, S; Casper, J; Porta, C; Schmidinger, M; et al. (2017-03)Introduction Currently, sunitinib is a standard of care in first-line treatment for metastatic renal cell carcinoma (mRCC). However, with the standard 4/2 schedule (sunitinib 50 mg/day; 4 consecutive weeks on treatment; ... -
Immune Checkpoint Inhibitors for Cancer Therapy in the COVID-19 Era.
Maio, M; Hamid, O; Larkin, J; Covre, A; Altomonte, M; et al. (2020-08)The potential immune intersection between COVID-19 disease and cancer therapy raises important practical clinical questions and highlights multiple scientific gaps to be filled. Among available therapeutic approaches to ... -
Immune-checkpoint inhibitors in melanoma and kidney cancer: from sequencing to rational selection.
Flynn, M; Pickering, L; Larkin, J; Turajlic, S (2018-01)Immune-checkpoint inhibitors (ICPIs), including antibodies against cytotoxic T-lymphocyte associated antigen 4 and programmed cell death protein 1, have been shown to induce durable complete responses in a proportion of ... -
Impact of COVID-19 pandemic on treatment patterns in metastatic clear cell renal cell carcinoma.
Aeppli, S; Eboulet, EI; Eisen, T; Escudier, B; Fischer, S; et al. (ELSEVIER, 2020-05-01)BACKGROUND: The coronavirus pandemic has provoked discussions among healthcare providers how to manage cancer patients when faced with the threat of severe acute respiratory syndrome related coronavirus 2 (SARS-CoV-2) ... -
Impact of depth of response on survival in patients treated with cobimetinib ± vemurafenib: pooled analysis of BRIM-2, BRIM-3, BRIM-7 and coBRIM.
Lewis, KD; Larkin, J; Ribas, A; Flaherty, KT; McArthur, GA; et al. (NATURE PUBLISHING GROUP, 2019-10-01)BACKGROUND: This pooled analysis investigated the prognostic value of depth of response in two cohorts of patients with BRAFV600-mutated metastatic melanoma treated with vemurafenib or cobimetinib plus vemurafenib. METHODS: ... -
Impact of initial treatment and prognostic factors on postprogression survival in BRAF-mutated metastatic melanoma treated with dacarbazine or vemurafenib ± cobimetinib: a pooled analysis of four clinical trials.
Ascierto, PA; Ribas, A; Larkin, J; McArthur, GA; Lewis, KD; et al. (2020-08-03)Background We sought to identify patient subgroups with distinct postprogression overall survival (ppOS) outcomes and investigate the impact of original treatment assignment and initial postprogression treatment (ppRx) on ... -
Integrative Analyses of Tumor and Peripheral Biomarkers in the Treatment of Advanced Renal Cell Carcinoma.
Choueiri, TK; Donahue, AC; Braun, DA; Rini, BI; Powles, T; et al. (AMER ASSOC CANCER RESEARCH, 2024-03-01)UNLABELLED: The phase III JAVELIN Renal 101 trial demonstrated prolonged progression-free survival (PFS) in patients (N = 886) with advanced renal cell carcinoma treated with first-line avelumab + axitinib (A+Ax) versus ... -
Lenvatinib for use in combination with everolimus for the treatment of patients with advanced renal cell carcinoma following one prior anti-angiogenic therapy.
O'Reilly, A; Larkin, J (2017-03)Introduction In patients with mRCC options for second line therapies, following progression on anti-angiogenic agents, that demonstrate a survival advantage in clinical trials have been limited. Recently a number of agents ... -
Lethal aplastic anemia caused by dual immune checkpoint blockade in metastatic melanoma.
Helgadottir, H; Kis, L; Ljungman, P; Larkin, J; Kefford, R; et al. (2017-07) -
Lifileucel, a Tumor-Infiltrating Lymphocyte Therapy, in Metastatic Melanoma.
Sarnaik, AA; Hamid, O; Khushalani, NI; Lewis, KD; Medina, T; et al. (2021-05-12)Purpose Effective treatment options are limited for patients with advanced (metastatic or unresectable) melanoma who progress after immune checkpoint inhibitors and targeted therapies. Adoptive cell therapy using ... -
Long-Term Outcomes With Nivolumab Plus Ipilimumab or Nivolumab Alone Versus Ipilimumab in Patients With Advanced Melanoma.
Wolchok, JD; Chiarion-Sileni, V; Gonzalez, R; Grob, J-J; Rutkowski, P; et al.<h4>Purpose</h4>In the phase III CheckMate 067 trial, durable clinical benefit was demonstrated previously with nivolumab plus ipilimumab and nivolumab alone versus ipilimumab. Here, we report 6.5-year efficacy and safety ...